Water-soluble camptothecin derivatives

Drugs of the Future

Volumn 22, Issue 11, 1997, Pages 1259-1266

  Bedeschi, Angelo ^a   Candiani, Ilaria ^a   Geroni, Cristina ^a   Capolongo, Laura ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; DNA TOPOISOMERASE; TOPOTECAN;

ANTINEOPLASTIC ACTIVITY; CYTOTOXICITY; DRUG DEVELOPMENT; DRUG SOLUBILITY; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; IN VITRO STUDY; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0031438522     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Wall, M.E., Wani, M.C., Cook, C.E., Palmer, K.H., McPhail, A.T., Sim, G.A. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminate. J Am Chem Soc 1966, 88: 3888.
2. Moertel, C.G., Schutt, A.J., Reitemeier, R.J., Hahn, R.G. Phase II study of camptothecin (NSC100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 1972, 56: 95.
3. Hsiang, Y.H., Hertzberg, R., Hecht, S., Liu, L.F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985, 260: 14873-8.
4. Hsiang, Y.H., Lihou, M.G., Liu, L.F. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989, 49: 5077.
5. Mattern, M.R., Mong, S.M., Bartus, H.F., Mirabelli, C.K., Crooke, S.T., Johnson, R.K. Relationship between the intracellular effects of camptothecins and the inhibition of DNA topoisomerase I in cultured L 1210 cells. Cancer Res 1987, 47: 1793.
6. Covey, J.M., Jaxel, C., Kohn, K.W., Pommier, Y. Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I. Cancer Res 1989, 49: 5016.
7. Jaxel, C., Kohn, K.W., Wani, M.C., Wall, M.E., Pommier, Y. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: Evidence for a specific receptor site and relation to antitumor activity. Cancer Res 1989, 49: 1465.
8. Giovanella, B.C., Stehlin, J.S., Wall, M.E. et al. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 1989, 246: 1046-8.
9. Husian, I., Mohler, J.L., Seigler, H.F., Bestermann, J.M. Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: Demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res 1994, 54: 539-46.
10. Van der Zee, A.G.J., Hollema, K., Jong, S. et al. P-Glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy. Cancer Res 1991, 51: 5915-20.
11. a) Pommier, Y., Jaxel, C., Heise, C.R., Kerrigan, D., Kohn, K.W. Structure-activity relationship of topoisomerase I inhibition by camptothecin derivatives: Evidence for the existence of a ternary complex. In: DNA Topoisomerases in Cancer. Potmesil, M., Kohn, K.W. (Eds.). Oxford University Press: New York 1991.
12. b) Su, T.L., Chou, T.C., Watanabe, K.A. DNA topoisomerase targeted anticancer agents: New trends and developments. In: DNA Topoisomerases in Cancer. Potmesil, M., Kohn, K.W. (Eds.). Oxford University Press: New York 1991.
13. Wall, M.E., Wani, M.C., Nicholas, A.W. et al. Plant antitumor agents. 30. Synthesis and structure activity of novel camptothecin analogs. J Med Chem 1993, 36: 2689-700.
14. Sawada, S., Matsuoka, S., Nokata, H. et al. Synthesis and antitumor activity of 20(S)-camptothecin derivatives: A-ring modified and 7,10-disubstituted camptothecins. Chem Pharm Bull 1991, 39: 3183-8.
15. Sawada, S., Yokokura, T., Miyasaka, T. Synthesis and antitumor activity of A-ring or E-lactone modified water-soluble prodrugs of 20(S)-camptothecin, including development of irinotecan hydrochloride trihydrate (CPT-11). Curr Pharm Des 1995, 1: 113-32.
16. Yaegashi, T., Sawada, S., Nagata, H., Furuta, T., Yokokura, T., Miyasaka, T. Synthesis and antitumor activity of 20(S)-camptothecin derivatives. A-ring-substituted 7-ethylcamptothecins and their E-ring-modified water soluble derivatives. Chem Pharm Bull 1994, 42: 2518-25.
17. Wall, M., Wani, M.C. Water-soluble esters of camptothecin compounds. WO 9602546 A1.
18. a) Kingsbury, W.D., Bohem, J.C., Jakas, D.R. et al. Synthesis of water-soluble (aminoalkyl) camptothecin analogues: Inhibition of topoisomerase I and antitumor activity. J Med Chem 1991, 34: 98-107.
19. b) Wood, J.L., Fortunak, J.M., Mastrocola, A., Mellinger, M., Burk, P.L. An efficient conversion of camptothecin to 10-hydroxycamptothecin. J Org Chem 1995, 60: 5739-40.
20. Luzzio, M.J., Bestermann, J.M., Emerson, D.L. et al. Synthesis and antitumor activity of novel water soluble derivatives of camptothecin as specific inhibitors of topoisomerase I. J Med Chem 1995, 38: 395-401.
21. Lakey, K., Sternbach, D.D., Groom, D.K., Emerson, D.L. et al. Water soluble inhibitors of topoisomerase I: Quaternary salt derivatives of camptothecin. J Med Chem 1996, 39: 713-9.
22. a) Akimoto, H., Ootsu, K., Kawamura, N. Preparation of dioxolopyranoindolizinoquinolines as antitumor agents. CA 2087898.
23. b) Xie, Z.-F., Ootsu, K., Akimoto, H. Convergent approach to water soluble camptothecin derivatives. Bioorg Med Chem Lett 1995, 5: 2189-94.
24. a) Terasawa, H., Ohsuki, S., Uoto, K. Hexacyclic compound. EP 495432.
25. b) Mitsui, I., Kumazawa, E., Hirota, Y. et al. A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo. Jpn J Cancer Res 1995, 86: 776-82.
26. a) Greenwald, R.B., Pendri, A. High molecular weight polymer-based prodrugs. WO 9623794.
27. b) Greenwald, R.B., Pendri, A., Conover, C., Gilbert, C., Yang, R., Xia, J. Drug delivery systems. 2. Camptothecin 20-O-polyethylene glycol ester transport forms. J Med Chem 1996, 39: 1938-40.
28. Angelucci, F., Suarato, A. Polymer bound camptothecin derivatives. WO 9510304.
29. Burke, T.G. Liposomal and micellar stabilisation of camptothecin drugs. US 5552156.
30. Sugarman, S.M., Zou, Y., Wasan, K. et al. Lipid-complexed camptothecin: Formulation and initial biodistribution and antitumor activity studies. Cancer Chemother Pharmacol 1996, 37: 531-8.
31. a) Burke, T.G., Staubus, A.E., Mishra, A.K. et al. Liposomal stabilization of camptothecin's lactone ring. J Am Chem Soc 1992, 114: 8318-9.
32. b) Burke, T.G., Mishra, A.K., Wani, M.C. et al. Lipid bilayer partitioning and stability of camptothecin drugs. Biochemistry 1993, 32: 5352-64.
33. Uehling, D.E., Nanthakumar, S.S., Croom, D. et al. Synthesis, topoisomerase I inhibitory activity, and in vivo evaluation of 11-azacamptothecin analogs. J Med Chem 1995, 38: 1106-18.
34. Wani, M.C., Nicholas, A.W., Manikumar, G., Wall, M.E. Plant antitumor agents. 25. Total synthesis and antileukemic activity of ring A substituted camptothecin analogues. Structure-activity correlations. J Med Chem 1987, 30: 1774-9.
35. Ohe, Y., Sasaki, Y., Shikai, T. et al. Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. J Natl Cancer Inst 1992, 84: 972-4.
36. Tanizawa, A., Fujimori, A., Fujimori, Y., Pommier, Y. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst 1994, 86: 836-42.
37. Emerson, D.L., Bestermann, J.M., Brown, H.R. et al. In vivo antitumor activity of two new seven-substituted water soluble camptothecin analogs. Cancer Res 1995, 55: 603-9.
38. Slichenmyer, W.J., Rwinsky, E.K., Donehower R.C. et al. The current status of camptothecin analogues as anticancer agents. J Natl Cancer Inst 1993, 85: 271-87.
39. a) Stork, G., Schultz, A.G. The total synthesis of dl-camptothecin. J Am Chem Soc 1971, 93: 4074-5.
40. b) Wani, M.C., Campbell, H.F., Brine, G.A., Kepler, J.A., Wall, M.E., Levine, S.G. Plant antitumor agents. IX. Total synthesis of dl-camptothecin. J Am Chem Soc 1972, 94: 3631-2.
41. a) Hutchinson, C.R. Camptothecin: Chemistry, biogenesis, and medicinal chemistry. Tetrahedron 1981, 37: 1047-65.
42. b) Cai, J.-C., Hutchinson, C.R. Camptothecin. In: The Alkaloids: Chemistry and Pharmacology, Vol. 21. Brossi, A. (Ed.). Academic Press: New York 1983, 101.
43. c) Cai, J.-C., Hutchinson, C.R. Camptothecin. Chem Heterocycl Compd 1983, 25: 753-81.
44. a) Wani, M.C., Nicholas, A.W., Wall, M.E. Plant antitumor agents. 28. Resolution of a key tricyclic synthon, 5′(RS)-1,5-dioxo-5′-hydroxy-2′H, 5′H,6′H,6′oxopyrano[3′,4′-f].Δ.6,8- tetrahydroindolizine: Total synthesis and antitumor activity of 20(S)- and 20(R)-camptothecin. J Med Chem 1987, 30: 2317-9.
45. b) Ejima, A., Terasawa, H., Sugimori, M., Tagawa, H. Antitumor agents. Part 2. Asymmetric synthesis of (S)-camptothecin. J Chem Soc Perkin Trans I 1990, 27.
46. c) Henegar, K.E., Sih, J.C. Novel intermediates and process for the manufacture of camptothecin derivatives (CPT-11) and related compounds. WO 9631513.
47. d) Henegar, K.E., Ashford, S.W., Baughman, T.A., Sih, J.C., Gu, R.-L. Practical asymmetric synthesis of (S)-4-ethyl-7,8-dihydro-4-hydroxy-1H-pyrano-[3,4-f]indolizine-3,6,10(4H)-trione, a key intermediate for the synthesis of irinotecan and other camptothecin analogs. J Org Chem 1997, 94: 6588-97.
48. a) Comins, D.L., Baevsky, M.F., Hong, H. A 10-step, asymmetric synthesis of (S)-camptothecin. J Am Chem Soc 1992, 114: 10971-2.
49. b) Comins, D.I., Hong, H., Jianhua, G. Asymmetric synthesis of camptothecin alkaloids: A nine-step synthesis of (S)-camptothecin. Tetrahedron Lett 1994, 35: 5331-4.
50. c) Comins, D.L., Hong, H., Saha, J.K., Jianhua, G. A six-step synthesis of (±)-camptothecin. J Org Chem 1994, 59: 5120-1.
51. a) Curran, D.P., Liu, H. New 4+1 radical annulations. A formal total synthesis of (±)-camptothecin. J Am Chem Soc 1992, 114; 5863-4.
52. b) Curran, D.P., Ko, S.-B. Synthesis of optically active α-hydroxy lactones by sharpless asymmetric dihydroxylations of ketene acetals, enol ethers, and ene lactones. J Org Chem 1994, 59: 6139-41.
53. c) Curran, D.P., Ko, S.-B., Josien, H. Cascade radical reactions of isonitriles: A second-generation synthesis of (20S)-camptothecin, topotecan, irinotecan, and GI-147211C. Angew Chem Int Ed Engl 1995, 32: 2683-4.
54. Shen, W., Coburn, C.A., Bornmann, W.G., Danishefsky, S.J. Concise total synthesis of dl-camptothecin and related anticancer drugs. J Org Chem 1993, 58: 611-7.
55. Fang, F.G., Xie, S., Lowery, M.W. Catalytic enantioselective synthesis of 20(S)-camptothecin: A practical application of the sharpless asymmetric dihydroxylation reaction. J Org Chem 1994, 59: 6142-3.
56. 2-camptothecin based on a sequence of palladium-catalysed reductions. Tetrahedron Lett 1995, 36: 9197-200.
57. b) Bedeschi, A., Zarini, F., Cabri, W. et al. Synthesis and antitumor activity of a new class of water soluble camptothecin derivatives. Bioorg Med Chem Lett 1996, 6: 671-4.
58. Geroni, C., Pesenti, E., Tagliabue, G. et al. Establishment of L1210 leukemia cells resistant to the distamycin-A derivative (FCE 24517): Characterisation and cross-resistance studies. Int J Cancer 1993, 53: 308-14.
59. Fassberg, J., Stella, V.J. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J Pharm Sci 1992, 81: 676-84.
60. Burke, T.G., Mi, Z. The structural basis of camptothecin interactions with human serum albumin: Impact on drug stability. J Med Chem 1994, 37: 40-6.
61. Scott, D.O., Bindra, D.S., Sutton, S.C. et al. Urinary and biliary disposition of the lactone and carboxylate forms of 20(S)-camptothecin in rats. Drug Metab Dispos 1994, 22: 438-42.
62. Burke, T.G., Mi, Z. Preferential binding of the carboxylate form of camptothecin by human serum albumin. Anal Biochem 1993, 212: 285-7.
63. Burke, T.G., Mi, Z. Ethyl substitution at the 7 position extends the half-life of 10-hydroxycamptothecin in the presence of human serum albumin. J Med Chem 1993, 36: 2580-2.
64. Mi, Z., Burke, T.G. Marked interspecies variations concerning the interactions of camptothecin with serum albumins: A frequency-domain fluorescence spectroscopic study. Biochemistry 1994, 33: 12540-5.
65. Mi, Z., Malak, H., Burke, T.G. Reduced albumin binding promotes the stability and activity of topotecan in human blood. Biochemistry 1995, 34: 13722-8.
66. Corigli, R. Unpublished results from this laboratory.
67. a) Beijnen, J.H. Clinical pharmacokinetics and pharmacodynamics of topotecan. 6th Conf DNA Topoisomerases Ther (Sept. 6-8, Amsterdam) 1995, Abst. S37.
68. b) Burris, H.A., Awada, A., Kuhn, J.G. et al. Phase I and pharmacokinetic studies of topotecan administered as a 72-or 120-h continuous infusion. Anti-Cancer Drugs 1994, 5: 394-402.
69. c) Rowinsky, E.K., Grochow, L.B., Hendricks, C.B. et al. Phase I and pharmacological study of topotecan: A novel topoisomerase I inhibitor. J Clin Oncol 1992, 10: 647-56.
70. Giovanella, B.C., Hinz, H.R., Kozielski, A.J. et al. Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin. Cancer Res 1991, 51: 3052-5.